Australia markets open in 18 minutes

Invex Therapeutics Ltd (IXC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0780-0.0020 (-2.50%)
At close: 12:26PM AEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/06/2023
30/06/2022
30/06/2021
30/06/2020
Operating expenses
Research development
5,559
7,400
2,963
1,139
1,300
Selling general and administrative
1,275
1,286
900.388
993.389
1,391
Total operating expenses
6,826
8,979
4,242
2,443
3,408
Operating income or loss
-6,826
-8,979
-4,242
-2,443
-3,408
Total other income/expenses net
-117.946
432.347
208.659
-
-117.946
Income before tax
-6,014
-7,750
-3,953
-2,284
-3,360
Income tax expense
0
0
0
0
0
Income from continuing operations
-6,014
-7,750
-3,953
-2,284
-3,360
Net income
-6,014
-7,750
-3,953
-2,284
-3,360
Net income available to common shareholders
-6,014
-7,750
-3,953
-2,284
-3,360
Basic EPS
-0.10
-0.10
-0.05
-0.03
-0.06
Diluted EPS
-0.10
-0.10
-0.05
-0.03
-0.06
Basic average shares
75,154
75,154
75,154
75,154
56,165
Diluted average shares
75,154
75,154
75,154
75,154
56,165